-transparent.png){kind=logo}
1. The present study investigates the effects of selective and a non-selective monoamine oxidase (MAO) inhibitors combined with L-tryptophan on MAO-A and -B activity, hypothalamic extracellular 5-hydroxytryptamine (5-HT) in vivo and the occurrence of the 5-HT behavioural syndrome. 2. Selective inhibition of intraneuronal MAO-A with MDL 72394 (0.5 mg kg-1, i.p.) had no effect on extracellular 5-HT and following administration of L-tryptophan (50 mg kg-1, i.p.) the 5-HT behavioural syndrome was not induced. 3. Selective inhibition of MAO-A at all sites with clorgyline (5 mg kg-1, i.p.) increased extracellular 5-HT but did not induce the 5-HT behavioural syndrome when combined with L-tryptophan administration. 4. Selective inhibition of MAO-B with selegiline (10 mg kg-1, i.p.) had no effect on extracellular 5-HT and the 5-HT behavioural syndrome was not observed after L-tryptophan administration. 5. Inhibition of MAO-A and -B with a higher and therefore non-selective, dose of MDL 72394 (2 mg kg-1) markedly increased extracellular 5-HT but failed to induce the 5-HT behavioural syndrome after L-tryptophan administration. 6. Inhibition of MAO-A and -B at all sites in the brain (tranylcypromine 20 mg kg-1, i.p. or clorgyline 5 mg kg-1 plus selegiline 10 mg kg-1) increased extracellular 5-HT and induced the behavioural syndrome on administration of L-tryptophan. 7. The results demonstrate that inhibition of MAO-A and -B both within amine neurones and elsewhere in the brain is essential for the development of the 5-HT behavioural syndrome. Whilst the syndrome is associated with increased extracellular 5-HT this does not appear necessarily to result in the syndrome and may indicate that increased extracellular 5-HT is not solely involved in the induction of the '5-HT behavioural syndrome'. Whilst the syndrome is associated with increased extracellular 5-HT this does not appear necessarily to result in the syndrome and may indicate that increased extracellular 5-HT is not solely involved in the induction of the '5-HT behavioural syndrome'.
A J Sleight, and
C A Marsden, and
K F Martin, and
M G Palfreyman
July 1959,
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
A J Sleight, and
C A Marsden, and
K F Martin, and
M G Palfreyman
March 1967,
Verhandlungen der Anatomischen Gesellschaft,
A J Sleight, and
C A Marsden, and
K F Martin, and
M G Palfreyman
November 1975,
British journal of pharmacology,
A J Sleight, and
C A Marsden, and
K F Martin, and
M G Palfreyman
March 1976,
Neuropharmacology,
A J Sleight, and
C A Marsden, and
K F Martin, and
M G Palfreyman
January 1991,
DICP : the annals of pharmacotherapy,
A J Sleight, and
C A Marsden, and
K F Martin, and
M G Palfreyman
May 1970,
British journal of pharmacology,
A J Sleight, and
C A Marsden, and
K F Martin, and
M G Palfreyman
May 1955,
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
A J Sleight, and
C A Marsden, and
K F Martin, and
M G Palfreyman
June 1971,
Journal of neurochemistry,
A J Sleight, and
C A Marsden, and
K F Martin, and
M G Palfreyman
January 1967,
The Journal of physiology,
A J Sleight, and
C A Marsden, and
K F Martin, and
M G Palfreyman
May 1988,
Journal of clinical chemistry and clinical biochemistry. Zeitschrift fur klinische Chemie und klinische Biochemie,
